Goodrays, Reviewed
One of the most visible CBD drinks in Britain, judged the way this desk judges everything: on the paperwork it publishes and the price of a milligram. The testing claim is everywhere; the certificates are not.
By Gemma Hartley
Goodrays has done something most UK CBD brands never manage: it has escaped the CBD aisle. Its 330ml cans are sold through a stockist network the company maps with its own store locator, with oils, gummies and magnesium drinks alongside. That reach raises the standard: a brand met by accident carries more of the burden of explaining itself. We judge on two things: what the paperwork says, and what a milligram costs.
The facts, up front
What it gets right
Goodrays states CBD content per unit, in plain figures, where a shopper will see it: 10mg in a can, 25mg in a gummy, 33mg in a dropper of either oil.
Better, the drinks pages carry the Food Standards Agency’s published acceptable daily intake of 10mg of CBD a day, state that a can contains exactly that, and add the standard advisory against use by children, in pregnancy or breastfeeding, or alongside medication.
The testing claim, read closely
Every product page carries the same assurance — “Third party tested and expertly dosed”. We do not doubt that testing happens. But on the pages a shopper passes through — the homepage, the drinks, gummies and oils pages, and the FAQ — we found no certificate of analysis, no batch-searchable lab report, and no link to either, as of this writing.
A testing claim is a statement of intent; a certificate of analysis is evidence — the thing that lets a buyer confirm the 25mg on the label is the 25mg in the sweet, and that controlled-cannabinoid content sits under the ceiling UK law sets per container. Nothing on those pages points to the FSA’s own register either. The site does carry a page headed “Most recent FSA guidance – our statement”; at the time of checking it rendered the heading and nothing beneath it.
The arithmetic
Work from the listed prices and the range divides cleanly. The oils are the value: Night Drops at £19.99 for a 1,000mg bottle is roughly 2p per milligram of CBD. The gummies, at £24.95 for thirty 25mg sweets, come to about 3.3p. The 500mg Zen Drops at £15.99 land near 3.2p — some sixty per cent more per milligram than the 1,000mg bottle of the same oil.
The drinks are a different proposition. Twelve cans at £24.99 buys 120mg of CBD, about 21p per milligram, or roughly ten times the oil. No scandal — a can is a beverage first, and nobody buys a soft drink by the milligram. But if CBD content is what you are shopping for, the cans are the dearest thing in this catalogue, and nothing on the product pages says so. One pricing note: the lower figure beside each homepage price is the Subscribe & Save rate, not a markdown — the company advertises “Save 20% on every order”. The arithmetic above uses the one-time prices.
Where the disclosure goes uneven
The intake figure and the advisory appear on the drinks pages. On the gummies and oils pages, at the time of checking, they did not — though a gummy is stated at 25mg and a dropper at 33mg, both above the 10mg-a-day figure the company quotes elsewhere. We offer no dosing advice, and the physical labels may carry more than the web pages do. But disclosure should not be strongest on the product holding the least.
The FAQ is the other soft spot: it tells readers that CBD “at high doses” has “proven effective in treating the symptoms of serious neurological disorders like epilepsy and multiple sclerosis”, and that it has been used to reduce inflammation and pain. Those are claims about the compound in general, not about anything in the basket, and we draw no regulatory conclusion — but they sit on a page selling food supplements. So, plainly: this is a food supplement sold to adults, not a medicine, and nothing in the range is offered as a remedy for any condition.
None of it is settled by the brand’s word, or ours. The FSA says no CBD extracts or isolates are currently authorised, and the public list exists so shoppers can see which products are attached to a credible application meanwhile. Being listed is not approval — and with the first authorisations targeted for around autumn 2026 per the regulator, that distinction matters more each month. The FSA’s guidance carries the intake figures Goodrays quotes.
Pros and cons
Verdict
The pharmacist’s summary: Goodrays is easy to like, easy to buy, and ahead of most of the shelf on per-unit clarity. Buy the cans and you are buying a soft drink with a small, labelled amount of CBD — fine, if you know the trade. What would lift this score is not a lower price but a lab-reports page: batch numbers, dates, potency panels, published openly. The claim is already on every product page; the evidence should not be the hard part.